FDA Grants Prime Medicine's PM359 RMAT Status, Expediting Review for CGD
PRME has more than doubled off its 52-week low of $1.555.
Summary
Prime Medicine has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for PM359, its investigational therapy for Chronic Granulomatous Disease (CGD). This designation, based on positive Phase 1/2 clinical data, provides significant benefits including intensive FDA guidance, eligibility for rolling and priority review, and potential for accelerated approval. This substantially de-risks and accelerates the development pathway for a key pipeline asset, which is crucial for a company that recently reported Q1 2026 results with a 'going concern' warning. PM359 also holds Fast Track, Orphan Drug, and Rare Pediatric Disease Designations.
At the time of this announcement, PRME was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $583.4M. The 52-week trading range was $1.55 to $6.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.